

27 November 2018

Chairman's 2018 Annual General meeting Address

Good morning ladies and gentlemen, welcome to the 2018 Annual General Meeting for NeuroScientific Biopharmaceuticals Limited.

My name is Brian Leedman and I'm Chairman of NeuroScientific. I will also Chair today's meeting. Thank you for taking the time to attend this morning.

I note that it is 10:00am and we have quorum, so I will officially declare this AGM open for proceedings.

I would now like to introduce you to your Board of Directors Dr Anton Uvarov, Mr Stephen Quantrill and Mr Matt Liddelow. Members of the Board standing for re-election today are: Dr Anton Uvarov, Mr Stephen Quantrill and myself.

I would also like to introduce the Company Secretary Mr Thomas Spencer. I note that we also have our Auditor from RSM in attendance.

The first item of business this morning is the consideration of the company's financial report, directors' report and auditor's report for the year ended 2018. These reports have been provided to members and are now before the meeting. Additional copies of these reports are available today.

I will make a few comments on this exciting year of progress for NeuroScientific before introducing our Managing Director and Chief Executive Officer who will provide his report to you. I will then proceed with the formal aspects of this AGM as set out in the Notice of Annual General Meeting. We will then be happy to take any questions from Shareholders in attendance today.

2018 has been one of great progress for NeuroScientific as the Company successfully listed on the ASX in an oversubscribed IPO. The monies raised will be used to progress our novel drug therapies for neurodegenerative conditions towards commercialisation. To this end, the team has been focused on two main areas; Alzheimer's disease and optic nerve degeneration. We are in the process of completing further animal studies in these areas prior to the enrolment of our first human patients in Phase I studies scheduled to commence early next year. These studies are designed to demonstrate the safety of our drugs that will generate interest from the large pharmaceutical companies searching for novel new treatments with tremendous commercial opportunities.

The Managing Director, Mr Matt Liddelow will discuss this in more detail but prior to handing over to Matt, I would like to thank my fellow Directors for their passion and dedication as we move forward on this exciting journey of discovery. I would also like to thank McRae Investments and Mr Harold Clough in particular, for his ongoing financial support and commitment to the success of our venture. I would also like to thank the participating Universities (UWA, UTAS and University of Copenhagen), collaboration partners in Covance and the Lions Eye Institute.



NeuroScientific
BIOPHARMACEUTICALS

Lastly, thank you to our shareholders. We have an exciting year ahead and I am confident that the developments made to date in combination with the significant milestones to come will bring prosperity in the new year.

I would now like to invite Matt Liddelov to address the meeting.

Managing Director and CEO's 2018 Annual General meeting Address

Thank you Brian and good morning to all in attendance today.

As Brian previously touched on, FY 2018 has been one of great progress for NeuroScientific but the Company is now heading into a period involving a lot of exciting activity in FY 2019.

Since becoming a public listed Company in July 2018, the management team have been busily working towards executing for Shareholders on all key objectives detailed within the Prospectus.

The Company's main focus involves the development of its lead drug candidate called EmtinB towards human clinical trials. EmtinB has the potential to be a first-in-class treatment for Alzheimer's disease and other degenerative conditions of nerve cells.


The Company will be reporting on the outcome of most of the key objectives that involve EmtinB during FY 2019, including:

- Completion of preclinical safety studies to support regulatory approval to start clinical trials;
- Further validation of EmtinB as a treatment for Alzheimer's disease in animal models; and
- Expansion of EmtinB's treatment indication, starting with degenerative conditions of the optic nerve.

We have been able to form strategic partnerships with organisations that are recognised globally as leaders in their respective industries to facilitate our research objectives. These partnerships include:

- Covance Labs, a global contract research organisation who have worked on all of the top 50 best-selling drugs available today. Covance are performing our preclinical safety studies involving EmtinB; and
- The Lions Eye Institute (LEI), a world leader in both research and clinical services in ophthalmology. The LEI are performing our preclinical studies involving EmtinB as a treatment for degenerative conditions of the optic nerve.

These studies involve ocular tissue distribution and safety studies in rabbits before progressing to treatment studies in glaucoma animal (pig) models. The LEI also have the capabilities to undertake clinical studies involving ocular administration of EmtinB.



NeuroScientific
BIOPHARMACEUTICALS

From a financial perspective, the Company is fully funded to achieve its key research objectives in FY 2019. As is to be expected, our Research and Development spend will be significant in FY 2019 as the Company executes on its research objectives.

We are also currently in the process of offering a non-renoncible Entitlement Issue to all eligible Shareholders. The non-renoncible Entitlement Issue was a planned offering to Shareholders and detailed in the Company's IPO Prospectus and subsequently via a formal Prospectus sent out late last week.

The Company has continued to actively raising awareness of its research activities and the potential of EmtinB as a treatment for neurodegenerative conditions by presenting at a number of conferences over the last 12-months, including: TechKnow Invest Roadshow; Biotech Invest 2018; BioShares Biotech 2018 Summit in Queenstown, NZ; Singapore Health Investor Day 2018. We will also be presenting at the upcoming 121 Tech Invest Singapore event in early December.

We will continue to raise wareness of NeuroScientific and EmtinB throughout FY 2019 in an effort to build a strong profile for the Company amongst both investor and biotech communities.


I personally would like to thank all Shareholders for supporting the Company's IPO in July and in particular McRae Investments for their support during the process and ongoing support throughout the previous years. I would also like to achknowledge the commitment and support of those involved at the University of Tasmania and University of Copenhagen.

Finally, I look forward to an exciting FY 2019 packed with development activity and look forward to reporting on a number of significant milestones.

Thank you for your time today.

NeuroScientific Biopharmaceuticals Ltd

AGM Presentation FY2018
27 November 2018



NeuroScientific
BIOPHARMACEUTICALS

Novel drug therapies for neurodegenerative
conditions

DISCLAIMER

The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

CORPORATE OVERVIEW

- ▶ Completed IPO listing on the ASX on the 27 July 2018
- ▶ Lead drug candidate funded through to completion of Phase I
- ▶ Lead drug candidate has the potential to treat a range of neurodegenerative conditions

Capital Structure

ASX code	NSB
Shares on issue	73,580,592
Price (close 26/11/2018)	\$0.17
Market cap	\$12.5M
Shares escrowed 12-months	1,906,269
Shares escrowed 24-months	19,349,506

BOARD & MANAGEMENT

BRIAN LEEDMAN

Co-founder of ResApp Health Ltd (ASX.RAP), Imugene Ltd (ASX:IMU) and Oncosil Ltd (ASX.OSL)

Non-executive Chairman

MATT LIDDELOW

>12 years experience commercialising medical devices and pharmaceuticals for Australian and multi-national companies including AstraZeneca.

MD & CEO

DR ANTON UVAROV

Founding director of Actinogen (ASX:ACW), conducting the largest Alzheimer's study in Australasia with 174 patients. Former analyst with Citigroup, New York.

Executive Director

STEPHEN QUANTRILL

20 years' experience in corporate advisory and company directorship, Executive Chairman of McRae Investments.

Non-executive Director

**Thomas Spencer,
CPA**

Company Secretary

COMPANY HIGHLIGHTS



Advanced preclinical lead drug candidate with multiple treatment indications



Strong strategic partnerships geared towards success



Validated strategy and business model



Experienced board and management team

TREATMENT MARKETS WITH UNMET NEED

Alzheimer's disease



48M people globally
have dementia

70% of dementias
Alzheimer's disease

US \$818B global
economic burden

Optic nerve conditions



5% of population
suffer vision loss due to
damaged optic nerve

60M people
affected by glaucoma

LEAD CANDIDATE: EMTINB



NOVEL

- Modeled on MT-II protein
- Binds LRP-1 receptors - novel MOA
- Stops cell death & stimulates regeneration



VALIDATED

- Preclinical in vitro models - successfully repeated
- Animal models




MULTIPLE INDICATIONS

- MOA: LRP-1 receptor ubiquitous
- Not directly targeting a process of disease

EVOLUTION OF EMTINB

MT-II Structure




- ▶ 61 amino acid length
- ▶ Binds divalent metal ions
- ▶ Difficult to manufacture

EmtinB Peptide




- ▶ 14 amino acid length
- ▶ Isolated from the β -domain of MT-II protein

EmtinB Peptide Dendrimer



- ▶ Synthesised as a dendrimer:
 - Increased potency and stability

EMTINB MECHANISM OF ACTION: Binding LRP-1 receptor



KEY MILESTONES FOR FY2019


Already Achieved in FY2019

- Public listing on the ASX
- Formed strategic research partnerships
- Executed on R&D plan

Planned for FY2019

- Completion of preclinical safety studies for EmtinB
- Further validation in another Alzheimer's disease animal model
- Expansion of EmtinB treatment indication; animal studies in degenerative conditions of the optic nerve
- Phase I Clinical trial

EMTINB DEVELOPMENT SCHEDULE



STRATEGIC PARTNERSHIPS



- ▶ Partner for preclinical safety studies
- ▶ Managed >3300 unique compounds
- ▶ >500 IND/CTD programs in the last 5-years
- ▶ Offer complete development solution from preclinical to clinical to market




- ▶ Partner for ophthalmology studies
- ▶ Developed 1st artificial cornea
- ▶ Developed 1st transgenic animal model for macular degeneration
- ▶ Glaucoma treatment recently acquired by global pharma Allergan

DEVELOPMENT PIPELINE

	Preclinical Phase			Clinical Phase	
	Lead optimisation	Animal efficacy	Safety & toxicology	Phase Ia	Phase Ib
Alzheimer's disease	EmtinB				
Degenerative conditions of the optic nerve	EmtinB				
Other Emtin peptides					

R&D EXPENSES FY2018 / FY2019



NEWSFLOW FOR FY 2019

